WithdrawnPhase 2NCT03086395
Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Studying Post-transplant lymphoproliferative disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Case Comprehensive Cancer Center
- Principal Investigator
- Deepa Jagadeesh, MD, MPH, M.DCleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
- Intervention
- Obinutuzumab(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2021
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03086395 on ClinicalTrials.govOther trials for Post-transplant lymphoproliferative disease
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06723457Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaNorthwestern University
- RECRUITINGPHASE1, PHASE2NCT07368634Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationDaihong Liu
- RECRUITINGPHASE2NCT06954805Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)Jennifer Amengual
- RECRUITINGPHASE1, PHASE2NCT07438067EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell TransplantationDaihong Liu
- ACTIVE NOT RECRUITINGNCT06422715PTLD: Multicentric Retrospective StudyFondazione Italiana Linfomi - ETS
- RECRUITINGPHASE1, PHASE2NCT06040320Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)Washington University School of Medicine
- RECRUITINGPHASE2NCT05453396Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell MalignanciesUniversity of Washington
- RECRUITINGPHASE2NCT05786040Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderTimothy Voorhees
See all trials for Post-transplant lymphoproliferative disease →